Nachrichten zur ABBVIE Aktie

AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B

AbbVie (ABBV) offers to buy Cerevel Therapeutics (CERE) for $8.7 billion. The acquisition will strengthen AbbVies neuroscience pipeline.…

AbbVie to buy drug developer Cerevel for $8.7 billion By Reuters

AbbVie to buy drug developer Cerevel for $8.7 billion…

AbbVie to buy drug developer Cerevel for $8.7 billion

…

AbbVie enters agreement to acquire Cerevel Therapeutics By Investing.com

AbbVie enters agreement to acquire Cerevel Therapeutics…

AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion

The deal is AbbVies latest attempt to expand its drug pipeline as its top-selling treatments, such as Humira, face generic…

AbbVie to buy Cerevel Therapeutics in $8.7 billion all-cash deal

AbbVie to buy Cerevel Therapeutics in $8.7 billion all-cash deal…

: AbbVie to buy Cerevel Therapeutics in $8.7 billion all-cash deal

AbbVie Inc. said late Wednesday it has agreed to buy Cerevel Therapeutics Holdings Inc. for $8.7 billion, saying that Cerevels…

AbbVie to Buy Cerevel Therapeutics for $8.7 Billion

…

Pharma Stocks With Nice Dividends: The RX Investors Need

Healthcare stocks like AbbVie and Johnson & Johnson are cash rich and offer solid dividend growth.…

Botulinum Toxin in Urology Market Hospital Segment Witnessed A Rapid Growth | Explained In Detail

Companies covered in this report AbbVie Inc., Merz Pharma; Ipsen Pharma; GALDERMA; Allergan PLC; Sun Pharmaceutical Industries Ltd.; Biovencer Healthcare…

AbbVie: 4 Hidden Keys Investors Must Know To Judge ImmunoGen Acquisition

…

AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time

…

AbbVie: $10 Billion Cancer Deal To Boost Growth

…

Pfizer, Idorsia and AbbVie drug brands lead the way in pharma digital marketing

What do popular Stanley insulated cups have in common with two pharma migraine brands? They’re all transformational digital brands, according…

ImmunoGen downgraded on Wall Street expecting AbbVie deal success

…

ImmunoGen: Attraktives Geschäft für Aktionäre - Aktienanalyse

Charlotte, NC (www.aktiencheck.de) - ImmunoGen-Aktienanalyse von Truist: Die Analysten von Truist streichen in einer aktuellen Aktienanalyse ihre Kaufempfehlung für die ImmunoGen-Aktie…

Abbvies $10bn swoop puts the spotlight on antibody-drug conjugates stocks

AbbVie Inc has announced the acquisition of ImmunoGen (NASDAQ:IMGN) for $10.1 billion in cash - a deal that takes into the…

AbbVie-Aktie: Deshalb gefällt diese Mega-Übernahme

Nach der Ankündigung einer 10 Milliarden US$ schweren Übernahme hat die Aktie von AbbVie (WKN: A1J84E) am Donnerstag um +3,5%…

AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion

AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors…

Pharma Stock Roundup: ABBV to Buy Immunogen, NVS Ups Mid-Term Sales View & More

AbbVie (ABBV) offers to acquire cancer biotech Immunogen for $10.1 billion. Novartis (NVS) raises its mid-term sales growth outlook by…

AbbVies $10bn Deal For ImmunoGen: Fundamentals And Rationale Explained

…

Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion

Shares of other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the…

Biotech-Milliardendeal: US-Pharmariese AbbVie schluckt ImmunoGen - Aktie verdoppelt sich nahezu!

AbbVie Pays $10.1 Billion for ImmunoGen to Expand Its Cancer Drug Portfolio

…

HBM Healthcare Investments AG: AbbVie erwirbt HBM-Portfoliounternehmen ImmunoGen für USD 10.1 Milliarden in bar

HBM Healthcare Investments AG / Schlagwort(e): Fusionen & Übernahmen AbbVie erwirbt HBM-Portfoliounternehmen ImmunoGen für USD 10.1 Milliarden in bar 30.11.2023…

EQS-News: AbbVie erwirbt HBM-Portfoliounternehmen ImmunoGen für USD 10.1 Milliarden in bar (deutsch)

AbbVie erwirbt HBM-Portfoliounternehmen ImmunoGen für USD 10.1 Milliarden in bar ^ HBM Healthcare Investments AG / Schlagwort(e): Fusionen &…

AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal

IMGN stock soared after AbbVie agreed to buy ImmunoGen for $10.1 billion, offering a rich premium for the maker of…

Immunogen shares surge on news of takeover by AbbVie By Investing.com

Immunogen shares surge on news of takeover by AbbVie…

ImmunoGen Stock Soars 80% on AbbVie’s $10.1 Billion Takeover

…

Pharmaceutical company AbbVie buying ImmunoGen in $10.1 billion deal

…

ImmunoGen: AbbVie greift zu! Aktienanalyse

Kulmbach (www.aktiencheck.de) - ImmunoGen-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die ImmunoGen-Aktie (ISIN:…